[{"id":"3a9311ae-a132-48fd-ac56-acb0fa708ff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05653271","created_at":"2022-12-16T15:58:33.900Z","updated_at":"2024-07-02T16:35:17.539Z","phase":"Phase 1","brief_title":"ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies","source_id_and_acronym":"NCT05653271","lead_sponsor":"Acepodia Biotech, Inc.","biomarkers":" CD20 • IFNG • IL6 • TNFA • IL2 • IL10","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • IFNG • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/21/2023","start_date":" 01/21/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-02-28"}]